These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 9395124

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP(85)VVHFFKNIVTP(96)RT in multiple sclerosis patients.
    Warren KG, Catz I.
    Mult Scler; 2000 Oct; 6(5):300-11. PubMed ID: 11064438
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.
    Warren KG, Catz I, Ferenczi LZ, Krantz MJ.
    Eur J Neurol; 2006 Aug; 13(8):887-95. PubMed ID: 16879301
    [Abstract] [Full Text] [Related]

  • 5. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.
    Krogsgaard M, Wucherpfennig KW, Cannella B, Hansen BE, Svejgaard A, Pyrdol J, Ditzel H, Raine C, Engberg J, Fugger L.
    J Exp Med; 2000 Apr 17; 191(8):1395-412. PubMed ID: 10770805
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.
    Wucherpfennig KW, Sette A, Southwood S, Oseroff C, Matsui M, Strominger JL, Hafler DA.
    J Exp Med; 1994 Jan 01; 179(1):279-90. PubMed ID: 7505801
    [Abstract] [Full Text] [Related]

  • 8. Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.
    Fridkis-Hareli M, Stern JN, Fugger L, Strominger JL.
    Hum Immunol; 2001 Aug 01; 62(8):753-63. PubMed ID: 11476898
    [Abstract] [Full Text] [Related]

  • 9. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.
    Madsen LS, Andersson EC, Jansson L, krogsgaard M, Andersen CB, Engberg J, Strominger JL, Svejgaard A, Hjorth JP, Holmdahl R, Wucherpfennig KW, Fugger L.
    Nat Genet; 1999 Nov 01; 23(3):343-7. PubMed ID: 10610182
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Optic neuritis anti-myelin basic protein synthetic peptide specificity.
    Warren KG, Catz I, Shutt K.
    J Neurol Sci; 1992 May 01; 109(1):88-95. PubMed ID: 1381412
    [Abstract] [Full Text] [Related]

  • 14. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.
    Fridkis-Hareli M, Santambrogio L, Stern JN, Fugger L, Brosnan C, Strominger JL.
    J Clin Invest; 2002 Jun 01; 109(12):1635-43. PubMed ID: 12070311
    [Abstract] [Full Text] [Related]

  • 15. Administration of myelin basic protein synthetic peptides to multiple sclerosis patients.
    Warren KG, Catz I.
    J Neurol Sci; 1995 Nov 01; 133(1-2):85-94. PubMed ID: 8583237
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis.
    Warren KG, Catz I.
    J Neuroimmunol; 1993 Mar 01; 43(1-2):87-96. PubMed ID: 7681451
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. pH dependent binding of high and low affinity myelin basic protein peptides to purified HLA-DR2.
    Mukku PV, Passmore D, Phan D, Nag B.
    Mol Immunol; 1995 Jun 01; 32(8):555-64. PubMed ID: 7541890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.